Pfizer CEO Albert Bourla said on Monday that a vaccine against Covid omicron variants will be ready in March, and the company has already started producing these doses.
“This vaccine will be ready in March,” Bourla told CNBC’s Squawk Box. “We (are) already starting to manufacture some of these risky quantities.”
Bourla said the vaccine will also target other variants that are circulating. He said that it is not yet clear whether the omicron vaccine is needed or how to use it, but Pfizer will prepare some doses because some countries hope to prepare them as soon as possible.
“Hopefully we can achieve something that can be better protected, especially to prevent infection, because of the protection of hospitalizations and serious diseases-it is reasonable now, as long as you have the current vaccine, let’s say the third dose,” Burla Say.
According to a study by the UK Health and Safety Agency, real-world data from the UK show that Pfizer and Moderna’s vaccines are only about 10% effective in preventing symptomatic infections caused by omicron within 20 weeks after the second vaccination. However, studies have found that the first two doses can still provide good protection against serious diseases.
According to this study, the effectiveness of booster injections in preventing symptomatic infections is as high as 75%.
The Chief Medical Adviser to the White House, Dr. Anthony Fauci, stated in December last year that there are No need for boosters specifically for omicron, Because the current booster can fight this variant very well.
Moderna CEO Stephane Bancel told CNBC earlier Monday that the company is developing a booster for omicron this fall, and it will enter clinical trials soon. Bansell said the government is in high demand when preparing for regular vaccination against the virus.
Bourla said it is unclear whether a fourth dose is needed. He said Pfizer will conduct experiments to determine if it needs to be taken again.
Israel has produced the fourth dose of Pfizer and Biological TechnologyThe vaccine can be used by people over 60 years of age, people with compromised immune systems, and health care workers.
Israel found that after the fourth dose of the vaccine, antibodies against the virus can be increased five-fold within a week.